ArticleClinical and translational radiation oncology2023

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer.

Michael Pennock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.